Studies on Anti-platelet Agents. V. Synthesis and Structur-Activity Relationship of 3-Substituted 5,6-Bis(4-methoxyphenyl)-1,2,4-triazines.
作者:Akito TANAKA、Hiroyoshi SAKAI、Takatoshi ISHIKAWA、Yukio MOTOYAMA、Hisashi TAKASUGI
DOI:10.1248/cpb.42.1835
日期:——
The syntheses and structure-activity relationships of a series of 3-substituted 5, 6-bis(4-methoxyphenyl)-1, 2, 4-triazines as anti-platelet agents based on cyclooxygenase (CO) inhibition are described. Of these compounds, 1-[5, 6-bis(4-methoxyphenyl)-1, 2, 4-triazin-3-yl]carbonyl-4-methylpiperazine (10) exhibited potent CO inhibition in vitro (IC50=2.8×10-7M) with vasodilatory activity (ED50=4.5×10-5M). Compound 10 also showed potent ex vivo activities, completely preventing platelet aggregation induced by arachidonic acid and collagen at 6h after oral administration of 3.2 and 1.0mg/kg. The ex vivo potency of 10 is more than three times that of aspirin. Moreover, 10 demonstrated no gastrointestinal side effect in rats even at 100mg/kg in spite of its potent CO inhibition activity, while aspirin, the most widely-used anti-platelet drug, showed gastrointestinal side effects in a dose-dependent manner (32, 100, and 320mg/kg) in our study. These results suggested that 10 is a very attractive candidate for development as an anti-platelet drug since an aspirin-like anti-platelet agent, based on CO inhibition and being free from gastrointestinal side effects, is a major goal of thromboembolic research.
本文介绍了一系列 3 取代的 5,6-双(4-甲氧基苯基)-1,2,4-三嗪类化合物的合成和结构-活性关系,这些化合物可作为基于环氧化酶(CO)抑制作用的抗血小板药物。在这些化合物中,1-[5, 6-双(4-甲氧基苯基)-1, 2, 4-三嗪-3-基]羰基-4-甲基哌嗪(10)在体外表现出强效的 CO 抑制作用(IC50=2.8×10-7M)和血管扩张活性(ED50=4.5×10-5M)。化合物 10 还显示出强大的体内外活性,在口服 3.2 和 1.0 毫克/千克后 6 小时,可完全阻止花生四烯酸和胶原蛋白诱导的血小板聚集。10 的体内外效力是阿司匹林的三倍多。此外,尽管 10 具有强大的一氧化碳抑制活性,但其 100 毫克/千克的剂量对大鼠没有胃肠道副作用,而阿司匹林作为最广泛使用的抗血小板药物,在我们的研究中却以剂量依赖的方式(32、100 和 320 毫克/千克)显示出胃肠道副作用。这些结果表明,10 是一种非常有吸引力的候选抗血小板药物,因为基于 CO 抑制且无胃肠道副作用的阿司匹林类抗血小板药物是血栓栓塞研究的主要目标。